Two biotech firms announce reverse mergers to list experimental bispecific antibody and BTK inhibitor on Nasdaq

Two biotech companies have each entered reverse merger agreements to become publicly traded on Nasdaq.

One firm, based in China, is developing a bispecific antibody and will use the merger to bring that candidate to market.

The other, a San Diego startup linked to Gossamer Bio, is advancing a Bruton's tyrosine kinase (BTK) inhibitor and will also list on Nasdaq.

Both companies aim to gain greater access to capital and visibility as they continue clinical development.